Biocompatible Polymer Composition for Blood-Brain Barrier Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic strategies lack efficacy in protecting and restoring the blood-brain barrier (BBB) from lesions and alterations due to pathologies or treatments such as chemotherapy and radiotherapy, and there are no compounds capable of directly promoting the repair and restoration of the BBB.
Innovation Solution
A biocompatible polymer with a specific formula (AaXxYy) is used to strengthen, repair, and restore the BBB, comprising monomers with R1COOR2 or R9(C=O)R10 groups and O or N-sulfonate groups, which can enhance the structure and function of the BBB.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic strategies are used to protect BBB components, then treatment approaches are provided, but no real efficacy or significant therapeutic effect is demonstrated
Solution Approach 1:
The patent changes the chemical parameters of the basement membrane by introducing modified proteoglycans with specific molecular weights and sulfation patterns. These parameter changes enable the proteoglycans to effectively inhibit MMPs and restore tight junctions, achieving real therapeutic efficacy where conventional approaches failed.
Solution Approach 2:
The invention uses composite material structure consisting of modified proteoglycans combined with specific carbohydrates and sulfation groups. This composite structure provides both the structural framework needed for basement membrane integration and the functional activity required for MMP inhibition and tight junction restoration, achieving both manufacturability and therapeutic effectiveness.
2Object-affected harmful factors
If BBB permeability is reduced to protect against neurotoxic agents, then neuronal protection is improved, but inflammatory responses and immune reactions may be exacerbated
Solution Approach 1:
The patent converts the harmful effect of MMP activation into a beneficial outcome by using modified proteoglycans that specifically inhibit MMPs. The proteoglycans transform the pathological process of basement membrane degradation into a protective mechanism where MMP inhibition prevents tight junction disruption and subsequent neurotoxic influx, while the anti-inflammatory properties of the proteoglycans simultaneously counteract harmful inflammatory responses.
3Strength
If tight junctions are strengthened to improve BBB integrity, then barrier function is enhanced, but the dynamic regulation capability may be reduced
Solution Approach 1:
The patent introduces dynamic characteristics into the basement membrane structure by using modified proteoglycans that can respond to physiological conditions. The proteoglycans maintain tight junction integrity under normal conditions while allowing appropriate dynamic regulation when needed, achieving both strength and adaptability in the BBB structure.
Data Source
AI summary
The present invention relates to a pharmaceutical composition for its application as a drug, in particular for use in the protection of the blood-brain barrier and/or the repair and/or the restoration of the blood brain barrier. The present invention finds an application in particular in the therapeutic, pharmaceutical and veterinary fields.